• br Conclusion br Acknowledgments This work was supported by

  2021-07-09

  

  Conclusion Acknowledgments This work was supported by Progetto PON - “Ricerca e Competitività 2007–2013” - PON01_01802: “Sviluppo di molecole capaci di modulare vie metaboliche intracellulari redox-sensibili per la prevenzione e la cura di patologie infettive, tumorali, neurodegenerative e lor

• It is very important to decide what the

  2021-07-09

  

  It is very important to decide what the best time of NIR laser irradiation is for the optimized PTT. So the best way is to monitor the biodistribution of the nanoparticles in various tissues (specially, in tumors) temporally and spatially after iv injection. Based on the combined functions of therap

• Upon Edn ligand binding endothelin

  2021-07-09

  

  Upon Edn ligand binding, endothelin receptors can induce a variety of intracellular signaling cascades leading to diverse cellular responses such as contraction in the case of smooth muscle cells, or cell growth and mitogenesis. Ednrs are expressed in a variety of cell types and tissues, for example

• br Introduction Abdominal aortic aneurysm AAA is a daily con

  2021-07-09

  

  Introduction Abdominal aortic aneurysm (AAA) is a daily concern in vascular surgery, as successful treatment is exclusively achieved by open or endovascular repair. Its prevalence is 2–11% among male smokers, and rupture the major complication, is associated with unacceptably high morbidity and m

• Three kinase inhibitors dasatinib type I imatinib type II

  2021-07-09

  

  Three kinase inhibitors dasatinib (type I), imatinib (type II) and nilotinib (type II), identified initially as inhibitors of tyrosine kinase BCR-ABL, were found to target DDRs in a chemical proteomic profiling study (Bantscheff et al., 2007, Hantschel et al., 2008). These tyrosine kinase inhibitors

• In this study we generated mice in which the

  2021-07-09

  

  In this study we generated mice in which the native Bcl6 locus was engineered to produce a form of Bcl6 containing a mutant RD2 domain that disrupts its repressor function. We found that RD2 domain is essential for pre-GC B cell differentiation and clustering into nascent GC within follicles, in par

• Several limitations of this study need to

  2021-07-08

  

  Several limitations of this study need to be acknowledged. First, although 200 patients were recruited into this study and completed assessments at baseline, only 89 patients completed the cognitive tests after 8weeks of treatment. The relatively long study period (8weeks) was the main reason for th

• The primary aim of this

  2021-07-08

  

  The primary aim of this study was to evaluate DAPK methylation as a tumor marker which is not only detected in the primary tumor but also in the serum of patients. We used matched pre-operative serum samples to determine the correlation of tumor and serum results. Despite an equal methylation freque

• The final test that was performed

  2021-07-08

  

  The final test that was performed was to determine whether the trigger points of the current limiters are stable across a wide temperature range. This test was performed within a thermal-vacuum chamber on each current limiter individually. All the current limiter trip currents were set to approximat

• SAR405838 br Using the same sort of methods we can also

  2021-07-08

  

  Using the same sort of methods, we can also address the proof of Theorem 1.2. The first part of the proof is made much easier if we use the “sieving” construction. Concretely, given a CMV operator , let denote the CMV operator with This induces a simple change in the spectrum; namely, if denotes

• N Cyclopentylmethyl analog exhibited fold less potent recept

  2021-07-07

  

  N-Cyclopentylmethyl analog 25 exhibited 2.3-fold less potent receptor affinity and 1.6-fold less potent antagonist activity. Among the compounds tested, the N-isobutyl analog 23 showed the most potent EP1 receptor affinity and antagonist activity. In summary, a series of 4-( 2-[alkyl(phenylsulfonyl

• br Clinical potential of ET receptor biased ligands Is

  2021-07-07

  

  Clinical potential of ET receptor biased ligands Is there a clinical need for ET receptor biased ligands? Evidence is strongest from research in epithelial ovarian cancer demonstrating that ET-1 stimulated ETA-mediated β-arrestin signalling leads to activation of the oncogenic mediator NF-κB [21]

• Results of the present study

  2021-07-07

  

  Results of the present study demonstrate that 25-OHC treatment of THP-1 monocytes induced vimentin intermediate filament reorganization to more cortical structures and a polarized phenotype (Fig. 5). Vimentin is the major intermediate filament protein present in leukocytes and plays an important rol

• ELUXA HM EMSI is an ongoing pivotal

  2021-07-07

  

  ELUXA 1 (HM-EMSI-202) is an ongoing pivotal Phase II global clinical trial, designed to further investigate the efficacy and safety of Olmutinib in patients T790M-positive NSCLC with acquired resistance after first-line EGFR TKIs. Primary endpoint is ORR according to RECIST 1.1, while secondary endp

• The expression of EBI has been found to be dysregulated

  2021-07-07

  

  The expression of EBI2 has been found to be dysregulated in several types of B cell malignancies and is thus reduced in e.g. diffuse large B-cell lymphomas [12] and chronic lymphocytic leukemia [13] and increased in post-transplantation lymphoproliferative disorders (PTLDs) [14]. EBI2 is also highly

15958 records 606/1064 page Previous Next First page 上5页 606607608609610 下5页 Last page